Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation and Depletion (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Depreciation and Depletion for 7 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion rose 4.13% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.3 million, a 1.68% increase, with the full-year FY2025 number at $22.3 million, up 1.68% from a year prior.
  • Depreciation and Depletion was $5.7 million for Q4 2025 at Beam Therapeutics, up from $5.6 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $5.7 million in Q4 2025 to a low of $1.4 million in Q1 2021.
  • A 5-year average of $4.3 million and a median of $5.0 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 133.33% in 2022, then fell 0.68% in 2025.
  • Beam Therapeutics' Depreciation and Depletion stood at $2.6 million in 2021, then surged by 54.12% to $3.9 million in 2022, then soared by 35.95% to $5.4 million in 2023, then rose by 1.51% to $5.4 million in 2024, then increased by 4.13% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Depreciation and Depletion are $5.7 million (Q4 2025), $5.6 million (Q3 2025), and $5.5 million (Q2 2025).